BOEHRINGER INGELHEIM INDIA PVT LTD

The Indian arm of Germany-based Boehringer Ingelheim recorded a revenue generation of Rs 30 crore in the biopharma space in FY 20-21, showing a growth of 30 per cent when compared to the revenue generated during FY 19-20 at Rs 23 crore. The year 2020 saw Mumbai-based Boehringer Ingelheim India receiving government’s approval of Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease in adults. The company also announced its partnership with Cipla to co-market three new oral anti-diabetics drugs Oboravo (Empagliflozin), Oboravo Met and Tiptengio (Empagliflozin+Linagliptin) in India.